- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Godfrey Pearlson on the Merits of Using Biological Measures to Classify Psychiatric Diseases
Current diagnostic tools, such as the Diagnostic and Statistical Manual of Mental Disorders, rely on symptoms to diagnose psychiatric diseases, but using biological measures instead could provide a more reliable, valid method of classifying these syndromes, said Godfrey Pearlson, MD, professor of psychiatry and neuroscience, Yale School of Medicine.
Current diagnostic tools, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM), rely on symptoms to diagnose psychiatric diseases, but using biological measures instead could provide a more reliable, valid method of classifying these syndromes, said Godfrey Pearlson, MD, professor of psychiatry and neuroscience, Yale School of Medicine.
Transcript
What are the advantages of using biologic measures to classify disease instead of the clinical DSM diagnoses?
Clinical DSM diagnoses are based on phenomenology, that is, what we observe in terms of patients’ symptoms and their clinical course. That’s basically where the rest of medicine was in the 17th and 18th century, before we could identify actual diseases where we knew their underlying cause, their etiology. If you rely only on symptoms, then you have something that’s akin to having fevers or dropsy or cough, where you have just a loose syndrome that everyone can agree on reliably but there’s no underlying validity. So if you just have people who are coughing up blood in medicine, then they could have pneumonia or lung cancer or severe asthma or a really bad cold, and there’s no way to sort them out without underlying biological measures.
So that’s pretty much where we are, I think, in psychiatry at the moment. Biology’s a reliable, valid method for potentially reclassifying these loose syndromes, figuring out what’s under the hood as far as biology, and that once we understand the origin of the illness and what’s wrong with the person biologically at a brain level, then we can move closer towards finding treatments that are individualized.
What are the consequences of the overlap in the current conditions encompassing psychosis in current diagnostic tools like the DSM?
Basically that we’re sort of groping around in the dark when it comes to defining illnesses. As I tried to suggest, it’s where medicine was in the 18th century before we understood what caused diseases. So before we had stethoscopes or otoscopes to look in people’s ears, we really couldn’t see what was going on and try and take measurements, even a basic measurement like temperature. Once you have reliable biological tools, it gives you an insight into what’s going on. Symptoms alone don’t really do that, cause symptoms overlap horribly all the way through medicine.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
